Giuseppe Ciaramella - Feb 5, 2020 Form 4/A - Amendment Insider Report for Beam Therapeutics Inc. (BEAM)

Role
President & CSO
Signature
By: Christine Bellon, Attorney-in-fact
Stock symbol
BEAM
Transactions as of
Feb 5, 2020
Transactions value $
$0
Form type
4/A - Amendment
Date filed
9/21/2021, 06:00 PM
Date Of Original Report
Feb 11, 2020
Next filing
Jun 30, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BEAM Stock Option (Right to Buy) Award $0 +27.3K $0.00 23.3K Feb 5, 2020 Common Stock 27.3K $0.67 Direct F1, F2, F3
transaction BEAM Stock Option (Right to Buy) Award $0 +13K $0.00 13K Feb 5, 2020 Common Stock 13K $4.22 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 11, 2020, the reporting person filed a Form 4 which inadvertently omitted certain options held by the reporting person on such date (the "Original Form 4").
F2 On May 8, 2018, the reporting person was granted an option to purchase 54,635 shares of common stock of Beam Therapeutics Inc. (the "Company"). The option award vests (i) fifty percent (50%) upon the Company achieving a certain development milestone related to base editing applications, and (ii) fifty percent (50%) upon the achievement of a closing price hurdle following the Company's initial public offering ("IPO") (which closing price hurdle has been achieved) (the "Price Condition"). The portion of the award subject to satisfaction of the Price Condition is scheduled to vest in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022. Upon the closing of the IPO, vesting of the portion of the option award subject to condition (ii) was tied only to the passage of time and the market price of the Company's securities and thus, 50% of the option award became reportable.
F3 (Continued from Footnote 2) The Original Form 4 failed to report the portion of the option award that became reportable upon the closing of the Company's IPO.
F4 On February 13, 2019, the reporting person was granted an option to purchase 25,957 shares of common stock of the Company. The option award vests (i) fifty percent (50%) upon the Company achieving a certain development milestone related to base editing applications, and (ii) fifty percent (50%) upon the achievement of a closing price hurdle following the Company's IPO (which closing price hurdle has been achieved). The portion of the award subject to satisfaction of the Price Condition is scheduled to vest in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022. Upon the closing of the IPO, vesting of the portion of the option award subject to condition (ii) was tied only to the passage of time and the market price of the Company's securities and thus, 50% of the option award became reportable. The Original Form 4 failed to report the portion of the option award that became reportable upon the closing of the Company's IPO.